Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

David A. Hyman, MD, JD, on Inclusive Shared Savings

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Amit Sanyal, MD: A Clinician’s Perspective

Advertisement

Advertisement




Nov
21
Today In Oncology
Reducing the Barriers to Receiving CAR T-Cell Therapy for Patients With Hematologic Malignancies
One Surgery Could Prevent Most Ovarian Cancers
ASTRO Experts Comment on the Results of the SUPREMO Trial
SLNB Alone vs Lymphadenectomy in Cervical Cancer
Traditional Approval Granted to Tarlatamab-dlle for Extensive-Stage SCLC
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo